Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroendocrine Tumors 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Giant Cell Tumor of Bone 1

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1avelumab 1aldesleukin 1Nivolumab 1Cyclophosphamide 1Axitinib 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × aldesleukin × 30 days × Clear all
NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡